Clinical trials have shown that UDCA enhances energy expenditure in hepatic cells, promotes mitochondrial biogenesis, and improves bile acid metabolism by inhibiting NF-kB and signal transducer and activator of transcription 3 (STAT3) phosphorylation, rendering it an effective treatment for NAFLD [85, 86]. The gene discussed is STAT3; the disease is metabolic dysfunction-associated steatotic liver disease.